Pitchai Balakumar

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/9906485/publications.pdf

Version: 2024-02-01

87 papers	3,495 citations	126907 33 h-index	149698 56 g-index
87 all docs	87 docs citations	87 times ranked	4984 citing authors

#	Article	IF	Citations
1	Unraveling the Differentially Articulated Axes of the Century-Old Reninâ€“Angiotensinâ€“Aldosterone System: Potential Therapeutic Implications. Cardiovascular Toxicology, 2022, 22, 246-253.	2.7	7
2	The potential modulatory role of curcumin on renal epithelial-to-mesenchymal transition in renal diseases. Pharmacological Research, 2021, 169, 105646.	7.1	3
3	Dysregulation of the renin-angiotensin system in septic shock: Mechanistic insights and application of angiotensin II in clinical management. Pharmacological Research, 2021, 174, 105916.	7.1	14
4	The physiologic and physiopathologic roles of perivascular adipose tissue and its interactions with blood vessels and the renin-angiotensin system. Pharmacological Research, 2021, 173, 105890.	7.1	11
5	The renin-angiotensin-aldosterone system: A century-old diversified system with several therapeutic avenues. Pharmacological Research, 2021, 174, 105929.	7.1	3
6	Mechanistic insights into hyperuricemia-associated renal abnormalities with special emphasis on epithelial-to-mesenchymal transition: Pathologic implications and putative pharmacologic targets. Pharmacological Research, 2020, 161, 105209.	7.1	22
7	A Contemporary Overview of PPARÎ±/Î³ Dual Agonists for the Management of Diabetic Dyslipidemia. Current Molecular Pharmacology, 2019, 12, 195-201.	1.5	23
8	A potential role of the renin-angiotensin-aldosterone system in epithelial-to-mesenchymal transition-induced renal abnormalities: Mechanisms and therapeutic implications. Pharmacological Research, 2019, 146, 104314.	7.1	34
9	Molecular targets of fenofibrate in the cardiovascular-renal axis: A unifying perspective of its pleiotropic benefits. Pharmacological Research, 2019, 144, 132-141.	7.1	23
10	Effects of pre and post-treatments with dipyridamole in gentamicin-induced acute nephrotoxicity in the rat. Regulatory Toxicology and Pharmacology, 2017, 84, 35-44.	2.7	16
11	Renin-angiotensin-aldosterone: An inclusive, an invigorative, an interactive and an interminable system. Pharmacological Research, 2017, 125, 1-3.	7.1	14
12	Effect of edaravone in diabetes mellitus-induced nephropathy in rats. Korean Journal of Physiology and Pharmacology, 2016, 20, 333.	1.2	5
13	Chronic oral administration of lowâ€dose combination of fenofibrate and rosuvastatin protects the rat heart against experimentally induced acute myocardial infarction. Fundamental and Clinical Pharmacology, 2016, 30, 394-405.	1.9	14
14	Prevalence and prevention of cardiovascular disease and diabetes mellitus. Pharmacological Research, 2016, 113, 600-609.	7.1	381
15	Drugs Targeting RAAS in the Treatment of Hypertension and Other Cardiovascular Diseases. , 2015, , 751-806.		2
16	A step ahead of PPARÎ³ full agonists to PPARÎ³ partial agonists: Therapeutic perspectives in the management of diabetic insulin resistance. European Journal of Pharmacology, 2015, 755, 50-57.	3.5	49
17	Cardiovascular drugs-induced oral toxicities: A murky area to be revisited and illuminated. Pharmacological Research, 2015, 102, 81-89.	7.1	17
18	Nephroprotective effect of catechin on gentamicin-induced experimental nephrotoxicity. Clinical and Experimental Nephrology, 2015, 19, 178-184.	1.6	32

#	Article	IF	Citations
19	Dapagliflozin: Glucuretic action and beyond. Pharmacological Research, 2014, 82, 34-39.	7.1	18
20	Catechin Averts Experimental Diabetes Mellitus-Induced Vascular Endothelial Structural and Functional Abnormalities. Cardiovascular Toxicology, 2014, 14, 41-51.	2.7	26
21	Low-dose dipyridamole treatment partially prevents diabetes mellitus-induced vascular endothelial and renal abnormalities in rats. International Journal of Cardiology, 2014, 172, 530-532.	1.7	24
22	Structural determinants for binding, activation, and functional selectivity of the angiotensin AT1 receptor. Journal of Molecular Endocrinology, 2014, 53, R71-R92.	2.5	62
23	A century old reninâ€“angiotensin system still grows with endless possibilities: AT1 receptor signaling cascades in cardiovascular physiopathology. Cellular Signalling, 2014, 26, 2147-2160.	3.6	143
24	Fenofibrate and dipyridamole treatments in low-doses either alone or in combination blunted the development of nephropathy in diabetic rats. Pharmacological Research, 2014, 90, 36-47.	7.1	18
25	Classical and pleiotropic actions of dipyridamole: Not enough light to illuminate the dark tunnel?. Pharmacological Research, 2014, 87, 144-150.	7.1	49
26	Fish Oil Blunted Nicotine-Induced Vascular Endothelial Abnormalities Possibly via Activation of PPARÎ³-eNOS-NO Signals. Cardiovascular Toxicology, 2013, 13, 110-122.	2.7	10
27	Differential effects of low-dose fenofibrate treatment in diabetic rats with early onset nephropathy and established nephropathy. European Journal of Pharmacology, 2013, 698, 388-396.	3.5	32
28	Possible involvement of PPARÎ³-associated eNOS signaling activation in rosuvastatin-mediated prevention of nicotine-induced experimental vascular endothelial abnormalities. Molecular and Cellular Biochemistry, 2013, 374, 61-72.	3.1	14
29	Adenosine Transport Blockade Restores Attenuated Cardioprotective Effects of Adenosine Preconditioning in the Isolated Diabetic Rat Heart: Potential Crosstalk with Opioid Receptors. Cardiovascular Toxicology, 2013, 13, 22-32.	2.7	24
30	Fenofibrate attenuates impaired ischemic preconditioning-mediated cardioprotection in the fructose-fed hypertriglyceridemic rat heart. Naunyn-Schmiedeberg's Archives of Pharmacology, 2013, 386, 319-329.	3.0	13
31	Cardiovascular pleiotropic actions of DPP-4 inhibitors: A step at the cutting edge in understanding their additional therapeutic potentials. Cellular Signalling, 2013, 25, 1799-1803.	3.6	25
32	The critical steps for successful research: The research proposal and scientific writing. Journal of Pharmacology and Pharmacotherapeutics, 2013, 4, 130-138.	0.4	13
33	Is hypertriglyceridemia a key detrimental factor or associative triggering factor for cardiovascular abnormalities?. Systematic Reviews in Pharmacy (discontinued), 2012, 3, 1.	0.2	0
34	Telmisartan in the Management of Diabetic Nephropathy: A Contemporary View. Current Diabetes Reviews, 2012, 8, 183-190.	1.3	20
35	Are PPAR alpha agonists a rational therapeutic strategy for preventing abnormalities of the diabetic kidney?. Pharmacological Research, 2012, 65, 430-436.	7.1	47
36	Is targeting eNOS a key mechanistic insight of cardiovascular defensive potentials of statins?. Journal of Molecular and Cellular Cardiology, 2012, 52, 83-92.	1.9	83

#	Article	IF	Citations
37	Submaximal PPARÎ³ activation and endothelial dysfunction: new perspectives for the management of cardiovascular disorders. British Journal of Pharmacology, 2012, 166, 1981-1992.	5.4	69
38	The combined strategy with PPARÎ± agonism and AT1 receptor antagonism is not superior relative to their individual treatment approach in preventing the induction of nephropathy in the diabetic rat. Pharmacological Research, 2012, 66, 349-356.	7.1	10
39	EDITORIAL [Hot Topic-II: PPAR Ligands and Cardiovascular Disorders: Friend or Foe (Guest Editors:) Tj ETQq1 1 0.784314 rgBT /Overlo	1.5	7
40	Interplay between statins and PPARs in improving cardiovascular outcomes: a doubleâ€edged sword?. British Journal of Pharmacology, 2012, 165, 373-379.	5.4	48
41	Healing the diabetic heart: Does myocardial preconditioning work?. Cellular Signalling, 2012, 24, 53-59.	3.6	48
42	Preconditioning the hyperlipidemic myocardium: Fact or fantasy?. Cellular Signalling, 2012, 24, 589-595.	3.6	30
43	How well do aliskiren's purported mechanisms track its effects on cardiovascular and renal disorders?. Cellular Signalling, 2012, 24, 1583-1591.	3.6	13
44	Fish oil and vascular endothelial protection: Bench to bedside. Free Radical Biology and Medicine, 2012, 53, 271-279.	2.9	68
45	Multifaceted cardiac signal transduction mediated by G protein-coupled receptors: Potential target sites where an unambiguous attention is needed for exploring new drugs for cardiovascular disorders. Biomedicine and Aging Pathology, 2011, 1, 197-202.	0.8	2
46	Potential cross-talk between (pro)renin receptors and Wnt/frizzled receptors in cardiovascular and renal disorders. Hypertension Research, 2011, 34, 1161-1170.	2.7	23
47	Pleiotropic actions of fenofibrate on the heart. Pharmacological Research, 2011, 63, 8-12.	7.1	32
48	Cardiovascular and Renal Pathologic Implications of Prorenin, Renin, and the (Pro)renin Receptor: Promising Young Players From the Old Renin-Angiotensin-Aldosterone System. Journal of Cardiovascular Pharmacology, 2010, 56, 570-579.	1.9	42
49	Effect of rosiglitazone in sodium arsenite-induced experimental vascular endothelial dysfunction. Archives of Pharmacal Research, 2010, 33, 611-618.	6.3	17
50	The Defensive Effect of Benfotiamine in Sodium Arsenite-Induced Experimental Vascular Endothelial Dysfunction. Biological Trace Element Research, 2010, 137, 96-109.	3.5	15
51	The Novel Role of Fenofibrate in Preventing Nicotine- and Sodium Arsenite-Induced Vascular Endothelial Dysfunction in the Rat. Cardiovascular Toxicology, 2010, 10, 227-238.	2.7	26
52	The low dose combination of fenofibrate and rosiglitazone halts the progression of diabetes-induced experimental nephropathy. European Journal of Pharmacology, 2010, 636, 137-144.	3.5	44
53	The multifaceted therapeutic potential of benfotiamine. Pharmacological Research, 2010, 61, 482-488.	7.1	93
54	Gentamicin-induced nephrotoxicity: Do we have a promising therapeutic approach to blunt it?. Pharmacological Research, 2010, 62, 179-186.	7.1	198

#	Article	IF	Citations
55	Multifarious molecular signaling cascades of cardiac hypertrophy: Can the muddy waters be cleared?â˜†. Pharmacological Research, 2010, 62, 365-383.	7.1	86
56	Ameliorative effect of combination of benfotiamine and fenofibrate in diabetes-induced vascular endothelial dysfunction and nephropathy in the rat. Molecular and Cellular Biochemistry, 2009, 320, 149-62.	3.1	73
57	Do resident renal mast cells play a role in the pathogenesis of diabetic nephropathy?. Molecular and Cellular Biochemistry, 2009, 330, 187-192.	3.1	20
58	Arsenic Exposure and Cardiovascular Disorders: An Overview. Cardiovascular Toxicology, 2009, 9, 169-176.	2.7	137
59	Vascular endothelial dysfunction: A tug of war in diabetic nephropathy?. Biomedicine and Pharmacotherapy, 2009, 63, 171-179.	5.6	59
60	The infarct size-limiting effect of ischemic postconditioning (IPOC) is suppressed in isolated hyperhomocysteinemic (Hhcy) rat hearts: The reasonable role of PKC-Î´. Biomedicine and Pharmacotherapy, 2009, 63, 787-791.	5.6	6
61	Emerging role of PPAR ligands in the management of diabetic nephropathy. Pharmacological Research, 2009, 60, 170-173.	7.1	37
62	The impairment of preconditioning-mediated cardioprotection in pathological conditions. Pharmacological Research, 2009, 60, 18-23.	7.1	62
63	Is nicotine a key player or spectator in the induction and progression of cardiovascular disorders?. Pharmacological Research, 2009, 60, 361-368.	7.1	69
64	Recent advances in pharmacotherapy for diabetic nephropathy: Current perspectives and future directions. Pharmacological Research, 2009, 60, 24-32.	7.1	58
65	Adenosine-A1 Receptors Activation Restores the Suppressed Cardioprotective Effects of Ischemic Preconditioning in Hyperhomocysteinemic Rat Hearts. Journal of Cardiovascular Pharmacology, 2009, 54, 204-212.	1.9	11
66	Possible Role of JAK-2 in Attenuated Cardioprotective Effect of Ischemic Preconditioning in Hyperhomocysteinemic Rat Hearts. Yakugaku Zasshi, 2009, 129, 523-535.	0.2	11
67	Pathophysiology of Diabetic Nephropathy: Involvement of Multifaceted Signalling Mechanism. Journal of Cardiovascular Pharmacology, 2009, 54, 129-138.	1.9	66
68	Hyperuricemia: Is it a Risk Factor for Vascular Endothelial Dysfunction and Associated Cardiovascular Disorders?. Current Hypertension Reviews, 2009, 5, 1-6.	0.9	6
69	Modulation of cardioprotective effect of ischemic pre- and postconditioning in the hyperhomocysteinemic rat heart. Methods and Findings in Experimental and Clinical Pharmacology, 2009, 31, 71.	0.8	15
70	Resident Cardiac Mast Cells: Are They the Major Culprit in the Pathogenesis of Cardiac Hypertrophy?. Basic and Clinical Pharmacology and Toxicology, 2008, 102, 5-9.	2.5	37
71	Potential target sites to modulate vascular endothelial dysfunction: Current perspectives and future directions. Toxicology, 2008, 245, 49-64.	4.2	61
72	Benfotiamine attenuates nicotine and uric acid-induced vascular endothelial dysfunction in the rat. Pharmacological Research, 2008, 58, 356-363.	7.1	40

#	Article	IF	Citations
73	Effect of bis (maltolato) oxovanadium (BMOV) in uric acid and sodium arsenite-induced vascular endothelial dysfunction in rats. International Journal of Cardiology, 2008, 128, 383-391.	1.7	37
74	Pre-conditioning and postconditioning to limit ischemiaâ€“reperfusion-induced myocardial injury: What could be the next footstep?. Pharmacological Research, 2008, 57, 403-412.	7.1	53
75	Pharmacological Interventions to Prevent Vascular Endothelial Dysfunction: Future Directions. Journal of Health Science, 2008, 54, 1-16.	0.9	15
76	Effect of Mast Cell Stabilizers in Hyperhomocysteinemia-induced Cardiac Hypertrophy in Rats. Journal of Cardiovascular Pharmacology, 2008, 51, 596-604.	1.9	35
77	PPAR Ligands: Are They Potential Agents for Cardiovascular Disorders?. Pharmacology, 2007, 80, 1-10.	2.2	60
78	PPAR dual agonists: Are they opening Pandora's Box?. Pharmacological Research, 2007, 56, 91-98.	7.1	168
79	Ameliorative Effect of Combination of Fenofibrate and Rosiglitazone in Pressure Overload-Induced Cardiac Hypertrophy in Rats. Pharmacology, 2007, 80, 177-184.	2.2	27
80	Effect of Fenofibrate in Pressure Overload-induced Experimental Cardiac Hypertrophy. International Journal of Biological Chemistry, 2007, 1, 104-110.	0.3	2
81	Peroxisome Proliferator Activated Receptor Agonists: Emerging Therapy for Cardiovascular Complications. Journal of Pharmacology and Toxicology, 2007, 2, 205-219.	0.2	6
82	Novel Use of Uric Acid and Sodium Arsenite to Induce Vascular Endothelial Dysfunction in Rats. Journal of Pharmacology and Toxicology, 2007, 2, 437-446.	0.2	9
83	Experimental Models for Vascular Endothelial Dysfunction. Trends in Medical Research, 2007, 2, 12-20.	0.2	15
84	Hyperhomocysteinemia and Cardiovascular Disorders: Is There a Correlation?. Trends in Medical Research, 2007, 2, 160-166.	0.2	11
85	Antiâ€Tumour Necrosis Factorâ€Î± Therapy in Heart Failure: Future Directions. Basic and Clinical Pharmacology and Toxicology, 2006, 99, 391-397.	2.5	65
86	The Possible Role of Caspaseâ€3 in Pathological and Physiological Cardiac Hypertrophy in Rats. Basic and Clinical Pharmacology and Toxicology, 2006, 99, 418-424.	2.5	36
87	Differential Role of Rho-Kinase in Pathological and Physiological Cardiac Hypertrophy in Rats. Pharmacology, 2006, 78, 91-97.	2.2	26